SalioGen Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
SalioGen Therapeutics, Inc. - overview
Established
2020
Location
Burlington, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2020, SalioGen Therapeutics, Inc. operates as a biotechnology company developing Gene Coding. Ray Tabibiazar serves as the CEO, and Chairman of the company as of 2021. In January 2022, SalioGen Therapeutics, Inc.
raised USD 115 million in series B funding co-led by new investors EPIQ Capital Group and GordonMD Global Investments, with participation from other new investors. The company is the developer of Gene Coding, a genetic medicine platform that uses its Exact DNA Integration Technology (EDIT) to give patients with inherited disorders, effective and broadly applicable non-viral gene therapy. The company's mammalian-derived genome editing technology will be employed in possibly curative nonviral gene therapy, allowing the healthcare industry to cure people in need. The company plans to use the series B funding received in January 2022 to expand its team, establish manufacturing and automation capabilities critical for Gene Coding, and accelerate the advancement of its preclinical programs.
Current Investors
PBM Capital Group, T Rowe Price, Fidelity Investments
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.saliogen.com
Verticals
HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.